Conversis Health launches new website 30 July 2009, Oxford: Conversis, a UK-based translation agency, has just launched a website to serve the needs of its translation and localisation clients in the pharmaceutical, medical device and biotech industries.
Medical translation and localisation requires specialist expertise because of the sensitivities around giving precise information and the abundance of complex medical terminology. Conversis has a network of expert medical translators based in more than 50 countries worldwide.
The company has worked with leading UK healthcare agencies, as well as some of the world’s largest pharmaceutical companies and clinical research organisations (CROs) on various projects relating to international clinical trials, the translation and localisation of pharmaceutical and medical device marketing material, patient information and prescribing information.
“Clients tell us that they like working with us because of our experience, our process and our meticulousness. With medical translation, there is no room for error. Our clients trust our service and that’s why they keep coming back,” says Gary Muddyman, managing director and CEO of Conversis.
“We understand that what we do, while vitally important, is just a small part of what is often a multimillion dollar project with the potential to save many lives. And that’s why we always hit our deadlines and deliver on every promise.
“Trusted. Proven. Rapid. That’s our guarantee.”
Find out more about medical translation.
Media contact For more information, please contact: Lisa Donovan Oxford Conversis Ltd Tel: + 44 (0) 1869 255 835 lisa.donovan@conversisglobal.com
Notes to editors:
About Conversis
Founded in 2003 and based in the United Kingdom, Conversis is now one of the world’s fastest growing and most innovative providers of Globalisation, Internationalisation, Localisation and Translation (GILT) services. In 2009, Conversis Health was launched to focus our growing expertise in medical translation.
News, views and debate on international business.